Importantly, melanoma studies have also reported that patients with high levels of circulating MDSCs have an inferior response to anti-PD-1 therapy, emphasising the potential of MDSC-targeted therapy to enhance the efficacy of ICB. This evidence concerns the gene PDCD1 and melanoma.